Scientists solve mystery of 'Frankenstein' DNA

November 10, 2014

Australian researchers have uncovered how the massive DNA molecules that appear in some tumours are formed like Frankenstein's monster, stitched together from other parts of the genome. This solves a decades-old mystery and explains how these tumours ensure their own survival.

The discovery also identified a potential drug target for treating cancers that are well known to harbour these molecules, dubbed 'neochromosomes'. Neochromosomes are giant, extra chromosomes found in up to three per cent of all cancers, most commonly in liposarcomas (tumours of fat tissue), sarcomas (soft tissue tumours) and some brain and blood cancers.

Research published today in the journal Cancer Cell, showed that spontaneous and catastrophic chromosomal 'explosions' trigger formation of neochromosomes. The shattered relics reassemble haphazardly, followed by a genetic frenzy of amplification and deletion. Genes known to be important for cancer development are massively amplified, assuring the cancer's survival.

The discovery was a collaborative venture between the Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research and Garvan Institute of Medical Research.

Chromosomes are the packages of genetic information found in all cells of the body. Each normal cell has 23 pairs. Neochromosomes were first identified in the 1950s, but their development was a mystery until now. They are large (often many times the size of the largest normal chromosome), and harbour many extra copies of 'oncogenes' (altered genes known to drive cancer development).

The researchers, led by Professor David Thomas and Associate Professor Tony Papenfuss, mapped the neochromosomes from liposarcomas, using next-generation DNA sequencing. The team then used mathematical modelling to reconstruct the sequence of events that caused the neochromosome to form, deducing that only chromosomal shattering could be to blame.

Associate Professor Papenfuss, from the Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre, said the research was like archaeology, sifting through the ruins of a past catastrophic event to understand the present.

"We showed that chromosome 12 shatters and its remnants form a ring of DNA in a haphazard fashion," he said. "As cells divide, and the circular chromosomes get copied and pulled into different cells, a constant abnormal morphing takes place. Small circles gradually become giant circles, progressively amplifying certain genes in what appears to be a selective process. The growing giant also sucks in DNA from all parts of the genome. At a certain point, the circle stops growing and becomes linear. By the time we look at tumour cells through the microscope, we see giant linear chromosomes."

Professor Thomas, Director of The Kinghorn Cancer Centre at the Garvan Institute, said the extent of the genetic rearrangement was truly astonishing. "These cancers manipulate the normal replication process in an ingenious way, creating a monster that can selectively steal and amplify the genes it needs to grow and survive," he said. "In some liposarcoma cell lines, DNA from every chromosome in the cell was found in the neochromosome, with between 60 and 100 copies of key oncogenes. Patient tumours also exhibited similar gene rearrangement."

The study also identified a potential therapeutic target to explore for treating liposarcomas, Professor Thomas said. "When the key oncogenes that were massively amplified in the cancer cells were blocked, the cancer cells died," he said.
Associate Professor Tony Papenfuss and Professor David Thomas led the research team, with Dr Dale Garsed from the Peter MacCallum Cancer Centre, Dr Owen Marshall from the Murdoch Children's Research Institute and Dr Vincent Corbin from the Walter and Eliza Hall Institute.

Garvan Institute of Medical Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to